{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Abbreviation', 'Definition', 'GO', \"Graves' ophthalmopathy or orbitopathy\", 'GO-QoL', \"Graves' Ophthalmopathy Quality of Life\", 'HbA1c', 'Glycated hemoglobin', 'HIPAA', 'Health Insurance Portability and Accountability Act', 'HIV', 'human immunodeficiency virus', 'HZN-001', 'Teprotumumab (previously RV 001)', 'IB', \"Investigator's brochure\", 'IBD', 'Inflammatory bowel disease', 'ICD', 'Intercanthal distance', 'ICF', 'Informed consent form', 'ICH', 'International Conference of Harmonization', 'IEC', 'Independent ethics committee', 'IGF-1R', 'Insulin-like growth factor-1 receptor', 'IL', 'Interleukin', 'IND', 'Investigational new drug', 'IRB', 'Institutional review board', 'ITT', 'Intent-to-treat', 'IV', 'Intravenous', 'IWRS', 'Interactive Web Response System', 'LR', 'Light reflex', 'LS', 'Least squares', 'mAb', 'Monoclonal antibody', 'MedDRA', 'Medical Dictionary for Regulatory Activities', 'MITT', 'Modified intent-to-treat', 'MMRM', 'Mixed-Model Repeated-Measures', 'NAb', 'Neutralizing antibody', 'NCI', 'National Cancer Institute', 'NCI-CTCAE', 'National Cancer Institute Common Terminology Criteria for Adverse Events', 'NCS', 'Not clinically significant', 'PBMC', 'Peripheral blood mononuclear cells', 'PD', 'Pharmacodynamic', 'PK', 'Pharmacokinetic', 'PopPK', 'Population pharmacokinetics', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 40 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Abbreviation', 'Definition', 'PP', 'Per-protocol', 'PVC', 'Polyvinyl chloride', 'PW', 'Premature withdrawal', 'q3W', 'Once every 3 weeks', 'QoL', 'Quality of life', 'qW', 'Once per week', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SST', 'Serum separator tube', 'SUSAR', 'Suspected unexpected serious adverse reaction', 'T1/2', 'Terminal phase elimination half-life', 'Tmax', 'Time to observed maximum concentration', 'TAO', 'Thyroid-associated ophthalmopathy', 'TEAE', 'Treatment-emergent adverse event', 'TED', 'Thyroid eye disease', 'TSH', 'Thyroid stimulating hormone', 'TSHR', 'Thyroid-stimulating-hormone receptor', 'TSH-R-Ab', 'TSH-Receptor stimulating, blocking and binding antibody', 'ULN', 'Upper limit of normal', 'VF subscale', 'Visual functioning subscale of GO-QoL', 'Vss', 'Volume of distribution at steady-state', 'WHODrug', 'World Health Organization Drug Dictionary', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 41 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '5', 'ETHICS', '5.1', 'Institutional Review Board/Independent Ethics Committee', 'The Principal Investigator (Investigator), the Sponsor and/or Contract Research Organization', '(CRO) authorized by the Sponsor will submit this protocol, any protocol modifications, and the', 'Informed Consent Form (ICF) and all applicable study documentation to be used in this study to', 'the appropriate Institutional Review Board (IRB) or Independent Ethics Committee (IEC) for', 'review and approval/favorable opinion. A letter confirming the IRB/IEC approval/favorable', 'opinion of the protocol the subject ICF and applicable study documentation, a list of the IRB/IEC', 'members involved in the vote as well as a statement that the IRB/IEC is organized and operates', 'according to Good Clinical Practice (GCP) and the applicable laws and regulations, must be', 'forwarded to the Sponsor or its designee prior to the enrollment of subjects into the study. A', 'copy of the approved ICF will also be forwarded to the Sponsor or its designee. Appropriate', 'reports on the progress of the study will be made to the IRB/IEC and the Sponsor or its designee', 'by the Investigator in accordance with applicable governmental regulations and in agreement', 'with the policy established by the Sponsor.', '5.2 Ethical Conduct of the Study', 'The Investigators will ensure that this study is conducted in a manner that fully conforms with', 'the principles of the \"Declaration of Helsinki\" or with the laws and regulations of the country in', 'which the research is conducted, whichever affords the greater protection to the individual. The', 'study must fully adhere to the principles outlined in \"Guideline for Good Clinical Practice\"', 'International Conference of Harmonization (ICH) Tripartite Guideline or with local law if it', 'affords greater protection to the subject. For studies conducted in the European Union/European', 'Economic Area (EU/EEA) countries, the Investigator will ensure compliance with the EU', 'Clinical Trial Directive [2001/20/EC]. For studies conducted in the USA or under US', 'Investigational New Drug (IND), the Investigator will additionally ensure adherence to the basic', 'principles of \"Good Clinical Practice\" as outlined in the current version of 21 Code of Federal', 'Regulations (CFR), subchapter D, part 312, \"Responsibilities of Sponsors and Investigators\",', 'part 50, \"Protection of Human Subjects\", and part 56, \"Institutional Review Boards\".', 'In other countries where a \"Guideline for Good Clinical Practice\" exists, the Sponsor and the', 'Investigators will strictly ensure adherence to the stated provisions.', '5.3 Subject Information and Consent', 'It is the responsibility of the Investigator, or a person designated by the Investigator (if', 'acceptable by local regulations), to obtain signed informed consent from each subject prior to', 'participating in this study after adequate explanation of the aims, methods, anticipated benefits,', 'and potential hazards of the study.', 'The Investigator or designee must also explain that the subjects are completely free to refuse to', 'enter the study or to withdraw from it at any time, for any reason.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 42 of 117']\n\n###\n\n", "completion": "END"}